Literature DB >> 26766490

High amyloid-β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study.

Fumihiko Yasuno1,2, Hiroaki Kazui3, Naomi Morita4, Katsufumi Kajimoto5, Masafumi Ihara5, Akihiko Taguchi5,6, Akihide Yamamoto2, Kiwamu Matsuoka1, Jun Kosaka1, Takashi Kudo7, Hidehiro Iida2, Toshifumi Kishimoto1, Kazuyuki Nagatsuka5.   

Abstract

OBJECTIVE: Previous studies have reported depressive symptoms in the preclinical stages of Alzheimer's disease (AD). The objective of this study was to determine whether depressive symptoms are associated with cortical amyloid burden. In order to do this, we measured cortical amyloid via (11) C-labeled Pittsburgh Compound B ([(11) C]PIB) uptake using positron emission tomography (PET) in cognitively normal subjects.
METHODS: We performed [(11) C]PIB-PET in 29 cognitively normal, older participants. Depressive symptoms were assessed using the 15-item Geriatric Depression Scale (GDS). Aβ deposition was quantified by binding potential (BPND ), and the association between cortical mean BPND values and GDS scores was evaluated. Analysis of parametric BPND images was performed to examine the relationship between regional BPND and GDS scores.
RESULTS: We found a positive correlation between depressive symptoms and mean cortical PIB-BPND in groups of subjects with middle to high PIB-BPND . There was little change in GDS-depression score between subjects with low and middle PIB-BPND levels, while an increase in GDS was shown in the high PIB-BPND group. The main BPND increase was localized to the precuneus/posterior cingulate cortex (PCu/PCC) in subjects with high PIB-BPND , and we found a significant positive relationship between PIB-BPND in this area and depressive symptoms.
CONCLUSIONS: Emotional dysregulation because of Aβ neuropathology in the PCu/PCC may relate to depressive symptoms. More specifically, we found that older, cognitively normal patients with depressive episodes were more likely to have underlying AD pathology. Thus, depressive symptoms may increase the predictive ability of the identification of future AD cases.
Copyright © 2016 John Wiley & Sons, Ltd. Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  11C-labeled Pittsburgh Compound B ([11C]PIB); Alzheimer's disease (AD); amyloid-β (Aβ); depressive symptoms; positron emission tomography (PET); precuneus/posterior cingulate cortex (PCu/PCC)

Mesh:

Substances:

Year:  2016        PMID: 26766490     DOI: 10.1002/gps.4409

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  25 in total

Review 1.  Advancing Drug Discovery and Development Using Molecular Imaging (ADDMI): an Interest Group of the World Molecular Imaging Society and an Inaugural Session on Positron Emission Tomography (PET).

Authors:  Shil Patel; Karl Schmidt; Jacob Hesterman; Jack Hoppin
Journal:  Mol Imaging Biol       Date:  2017-06       Impact factor: 3.488

2.  Sex Differences in the Relationship between Depressive Symptoms and Risk of Amnestic Mild Cognitive Impairment.

Authors:  Erin E Sundermann; Mindy J Katz; Richard B Lipton
Journal:  Am J Geriatr Psychiatry       Date:  2016-09-09       Impact factor: 4.105

3.  Longitudinal Association of Amyloid Beta and Anxious-Depressive Symptoms in Cognitively Normal Older Adults.

Authors:  Nancy J Donovan; Joseph J Locascio; Gad A Marshall; Jennifer Gatchel; Bernard J Hanseeuw; Dorene M Rentz; Keith A Johnson; Reisa A Sperling
Journal:  Am J Psychiatry       Date:  2018-01-12       Impact factor: 18.112

4.  Shared effects of the clusterin gene on the default mode network among individuals at risk for Alzheimer's disease.

Authors:  Qing Ye; Fan Su; Hao Shu; Liang Gong; Chun-Ming Xie; Hong Zhou; Zhi-Jun Zhang; Feng Bai
Journal:  CNS Neurosci Ther       Date:  2017-02-23       Impact factor: 5.243

5.  Prepandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults.

Authors:  Muge Akinci; Cleofé Peña-Gómez; Gregory Operto; Sherezade Fuentes-Julian; Carme Deulofeu; Gonzalo Sánchez-Benavides; Marta Milà-Alomà; Oriol Grau-Rivera; Nina Gramunt; Arcadi Navarro; Carolina Minguillón; Karine Fauria; Ivonne Suridjan; Gwendlyn Kollmorgen; Anna Bayfield; Kaj Blennow; Henrik Zetterberg; José Luis Molinuevo; Marc Suárez-Calvet; Juan Domingo Gispert; Eider M Arenaza-Urquijo
Journal:  Neurology       Date:  2022-08-02       Impact factor: 11.800

6.  State-dependent alterations in cerebrospinal fluid Aβ42 levels in cognitively intact elderly with late-life major depression.

Authors:  Nunzio Pomara; Davide Bruno; Ricardo S Osorio; Chelsea Reichert; Jay Nierenberg; Antero S Sarreal; Raymundo T Hernando; Charles R Marmar; Thomas Wisniewski; Henrik Zetterberg; Kaj Blennow
Journal:  Neuroreport       Date:  2016-09-28       Impact factor: 1.837

7.  Relationship between neuropsychiatric symptoms and Alzheimer's disease pathology: An in vivo positron emission tomography study.

Authors:  Fumihiko Yasuno; Hiroyuki Minami; Hideyuki Hattori
Journal:  Int J Geriatr Psychiatry       Date:  2020-11-15       Impact factor: 3.485

8.  Preliminary Evidence That Cortical Amyloid Burden Predicts Poor Response to Antidepressant Medication Treatment in Cognitively Intact Individuals With Late-Life Depression.

Authors:  Warren D Taylor; Brian D Boyd; Damian Elson; Patricia Andrews; Kimberly Albert; Jennifer Vega; Paul A Newhouse; Neil D Woodward; Hakmook Kang; Sepideh Shokouhi
Journal:  Am J Geriatr Psychiatry       Date:  2020-09-28       Impact factor: 4.105

9.  Longitudinal Cognitive Profiles by Anxiety and Depressive Symptoms in American Older Adults With Subjective Cognitive Decline.

Authors:  Sangwoo Ahn; Michelle A Mathiason; Fang Yu
Journal:  J Nurs Scholarsh       Date:  2021-08-03       Impact factor: 3.176

10.  Default mode network dissociation linking cerebral beta amyloid retention and depression in cognitively normal older adults.

Authors:  Sheng-Min Wang; Nak-Young Kim; Yoo Hyun Um; Dong Woo Kang; Hae-Ran Na; Chang Uk Lee; Hyun Kook Lim
Journal:  Neuropsychopharmacology       Date:  2021-06-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.